/SI
SI Stock - SHOULDER INNOVATIONS, INC.
Healthcare|Medical - SpecialtiesNYSE
$13.60-4.02%
$0.57 (-4.02%) • Jan 13
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.41
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+69.1%upside
Target: $23.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$13.46 – $13.74
TARGET (TP)$23.00
STOP LOSS$12.51
RISK/REWARD1:8.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-7.53
52W High$17.94
52W Low$10.92
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 |
|---|---|---|
| Revenue | $31.62M | $19.27M |
| Gross Profit | $24.34M | $15.27M |
| Gross Margin | 77.0% | 79.2% |
| Operating Income | $-14,653,000 | $-10,864,000 |
| Net Income | $-15,619,000 | $-12,655,000 |
| Net Margin | -49.4% | -65.7% |
| EPS | $-0.77 | $-0.63 |
Company Overview
Shoulder Innovations, Inc. manufactures medical devices. It has developed a shoulder replacement system. The company was founded by Stephen B. Gunther and Michael DeVries in 2009 and is headquartered in Grand Rapids, MI.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
29%
Hold / Neutral
9
53%
Sell / Underperform
3
18%
Analyst Consensus🔴 Bearish
5 Bullish12 Neutral/Bearish
Price Targets
$36
Average Target
↑ 166.8% Upside
Now
$4
Low
$36
Average
$135
High
Based on 21 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 25th 2025 | Goldman | Initiation | Buy | $20 |
| August 25th 2025 | Piper Sandler | Initiation | Overweight | $18 |
| August 25th 2025 | BTIG Research | Initiation | Buy | $23 |
| August 25th 2025 | Jefferies | Initiation | Buy | $19 |
| March 6th 2023 | Compass Point | Downgrade | Sell | - |
| March 6th 2023 | Wedbush | Downgrade | Underperform | $4← $9 |
| March 2nd 2023 | Compass Point | Downgrade | Neutral | $10← $16 |
| March 2nd 2023 | JP Morgan | Downgrade | Underweight | - |
| March 2nd 2023 | Canaccord Genuity | Downgrade | Hold | $9← $25 |
| March 1st 2023 | Keefe Bruyette | Downgrade | Market Perform | $16← $25 |
| January 9th 2023 | Wedbush | Downgrade | Neutral | $9← $15 |
| January 6th 2023 | Craig Hallum | Downgrade | Hold | $14← $36 |
| January 6th 2023 | BofA Securities | Downgrade | Underperform | $8← $37 |
| January 6th 2023 | JP Morgan | Downgrade | Neutral | $14← $30 |
| December 12th 2022 | Wedbush | Reiterated | Outperform | $30← $45 |
Earnings History & Surprises
SIBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-165.53
Q3 2025
EPS Surprise History
Q3 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2026 | Jul 24, 2026 | $-0.42 | — | — | — |
Q4 2025 | Nov 11, 2025 | — | — | — | — |
Q3 2025 | Sep 9, 2025 | — | $-165.53 | — | — |
Latest News
Shoulder Innovations Partners With Interventional Systems To Develop Portable Micro-Robotic Platform For Total And Reverse Shoulder Arthroplasty Integrated Into ProVoyance Ecosystem For ASC Use
📈 PositiveBenzinga•Dec 3, 2025, 12:04 PM
Morgan Stanley Maintains Overweight on Shoulder Innovations, Raises Price Target to $23
📈 PositiveBenzinga•Dec 2, 2025, 05:53 PM
Piper Sandler Reiterates Overweight on Shoulder Innovations, Maintains $18 Price Target
➖ NeutralBenzinga•Nov 12, 2025, 05:05 PM
Shoulder Innovations shares are trading higher after the company reported better-than-expected Q3 sales results and raised its FY25 sales guidance above estimates.
📈 PositiveBenzinga•Nov 12, 2025, 02:17 PM
Shoulder Innovations Raises FY2025 Sales Guidance from $42.000M-$44.000M to $45.000M-$46.000M vs $43.173M Est
📈 PositiveBenzinga•Nov 11, 2025, 10:45 PM
Shoulder Innovations shares are trading higher after the company reported better-than-expected Q3 sales results.
📈 PositiveBenzinga•Nov 11, 2025, 09:14 PM
Shoulder Innovations Q3 EPS $(0.64) Misses $(0.39) Estimate, Sales $11.756M Beat $9.876M Estimate
➖ NeutralBenzinga•Nov 11, 2025, 09:06 PM
Shoulder Innovations Launches InSet 70 Implant To Improve Outcomes In Shoulder Replacement Surgeries
📈 PositiveBenzinga•Sep 22, 2025, 10:21 AM
BTIG Reiterates Buy on Shoulder Innovations, Maintains $23 Price Target
📈 PositiveBenzinga•Sep 9, 2025, 03:10 PM
Shoulder Innovations Sees FY25 Revenue $42M-$44M
📈 PositiveBenzinga•Sep 9, 2025, 11:15 AM
Shoulder Innovations Q2 Revenue $11M, Up 33% YoY; EPS $ (165.53)
➖ NeutralBenzinga•Sep 9, 2025, 11:15 AM
Morgan Stanley Initiates Coverage On Shoulder Innovations with Overweight Rating, Announces Price Target of $18
📈 PositiveBenzinga•Aug 26, 2025, 02:28 PM
Shoulder Innovations shares are trading higher after multiple firms initiated coverage on the stock.
📈 PositiveBenzinga•Aug 25, 2025, 05:04 PM
Goldman Sachs Initiates Coverage On Shoulder Innovations with Buy Rating, Announces Price Target of $20
📈 PositiveBenzinga•Aug 25, 2025, 04:03 PM
Piper Sandler Initiates Coverage On Shoulder Innovations with Overweight Rating, Announces Price Target of $18
📈 PositiveBenzinga•Aug 25, 2025, 02:38 PM
Jefferies Initiates Coverage On Shoulder Innovations with Buy Rating, Announces Price Target of $19
📈 PositiveBenzinga•Aug 25, 2025, 11:10 AM
Frequently Asked Questions about SI
What is SI's current stock price?
SHOULDER INNOVATIONS, INC. (SI) is currently trading at $13.60 per share. The stock has moved -4.02% today.
What is the analyst price target for SI?
The average analyst price target for SI is $23.00, based on 1 analyst.
What sector is SHOULDER INNOVATIONS, INC. in?
SHOULDER INNOVATIONS, INC. operates in the Healthcare sector, specifically within the Medical - Specialties industry. The company is traded on the NYSE exchange.
What is SI's market cap?
SHOULDER INNOVATIONS, INC. has a market capitalization of $0.28 billion, making it a small-cap company.
Does SI pay dividends?
No, SHOULDER INNOVATIONS, INC. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAARD
Aardvark Therapeutics, Inc. Common Stock
$15.39
Mkt Cap: $0.3B
ASMB
Assembly Biosciences, Inc.
$31.60
Mkt Cap: $0.3B
ENTA
Enanta Pharmaceuticals, Inc.
$13.13
Mkt Cap: $0.3B
EPRX
Eupraxia Pharmaceuticals Inc.
$8.31
Mkt Cap: $0.3B
INGN
Inogen, Inc.
$6.22
Mkt Cap: $0.2B
MDXH
MDxHealth S.A.
$3.61
Mkt Cap: $0.2B
NAUT
Nautilus Biotechnology, Inc.
$1.96
Mkt Cap: $0.2B
NNOX
Nano-X Imaging Ltd.
$3.04
Mkt Cap: $0.2B
OM
Outset Medical, Inc.
$5.12
Mkt Cap: $0.1B
SNWV
SANUWAVE Health, Inc.
$28.57
Mkt Cap: $0.2B
Explore stocks similar to SI for comparison